MS Pharma has officially opened the first biologics manufacturing plant in the Middle East, strategically located in Saudi Arabia. The plant has received Good Manufacturing Practices (GMP) approval from the Saudi Food and Drug Authority (SFDA), establishing a hub for advanced biopharmaceutical production in the Middle East and North Africa (MENA) region.
With formulation, filling and finishing, and freeze-drying capabilities, this $50 million investment positions MS Pharma as the region’s leading biologics company. It also positions the company as a trusted partner for global pharmaceutical companies seeking to access the Saudi Arabian market and the MENA region through local and contract manufacturing solutions for broader international markets.
The factory is designed to meet the highest international regulatory standards, including the US EMA and FDA, and specialises in monoclonal antibodies and complex peptides, two of the world’s most in-demand classes of biologic treatments. The plant also has the region’s first in-house bioanalytical testing laboratories, eliminating the need for overseas testing services and accelerating time to market for critical treatments.
